secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0001213900-24-021251
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics Q4 2023 update: cash $8.5M, tecarfarin expanded to LVADs and APS
--------------------------------------------------------------------------------

- Q4 2023 operating expenses (excl. non-cash) totaled $1,160,000; cash used in ops $694,000.
- Cash and equivalents at Dec 31, 2023: $8.5 million.
- Expanded tecarfarin development to include LVAD and APS patients, addressable market >$2B/yr in US.
- Appointed Jeff Cole as COO, overseeing manufacturing, supply chain, IP, and partnering.
- Engaged The Sage Group to explore strategic partnerships, co-development, and licensing for tecarfarin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390024021251/0001213900-24-021251-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390024021251/ea0201508-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-021251

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer